<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03561805</url>
  </required_header>
  <id_info>
    <org_study_id>PARE</org_study_id>
    <nct_id>NCT03561805</nct_id>
  </id_info>
  <brief_title>Prolonged Continuous ECG Monitoring Prior to Transcatheter Aortic Valve Implantation</brief_title>
  <official_title>Prolonged Continuous ECG Monitoring Prior to TrAnscatheter AoRtic ValvE Implantation: the PARE Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with severe aortic stenosis candidates for a TAVI procedure harbor a high burden of
      silent arrhythmic events. Pre-procedural detection of such arrhythmias should help the
      investigators to implement specific therapeutic measures that may improve patient outcomes
      and reduce hospitalization length post-TAVI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective registry including patients accepted by the heart team for a TAVI
      procedure. Patients will undergo a prolonged continuous ECG monitoring using the CardioSTAT®
      device within the 3 months prior to the TAVI procedure. The duration of the ECG monitoring
      will be of 1 week. There will be no restriction regarding the type of valve and approach used
      for the TAVI procedure. All type of arrhythmic events will be recorded, as well as the
      specific therapeutic measures implemented upon the occurrence of the arrhythmic event.
      Following the TAVI procedure, the patients will be monitored (telemetry) until hospital
      discharge. All arrhythmic events during the hospitalization period will be recorded. Clinical
      follow-up will be performed at 30 days, and 1 year post-TAVI, and yearly thereafter up to
      5-year follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Anticipated">June 1, 2026</completion_date>
  <primary_completion_date type="Actual">January 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Arrhythmic events</measure>
    <time_frame>Within 3 months prior to the TAVI procedure</time_frame>
    <description>Incidence and type of arrhythmic events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Therapeutic changes</measure>
    <time_frame>Within 3 months prior to the TAVI procedure</time_frame>
    <description>incidence of arrhythmic events identified by the device leading to therapeutic changes prior to the TAVI procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Atrial fibrillation</measure>
    <time_frame>Within 3 months prior to the TAVI procedure</time_frame>
    <description>incidence of atrial fibrillation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial fibrillation</measure>
    <time_frame>Within 3 months prior to the TAVI procedure</time_frame>
    <description>duration of atrial fibrillation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrioventricular block</measure>
    <time_frame>Within 3 months prior to the TAVI procedure</time_frame>
    <description>incidence of advanced atrioventricular block</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe bradycardia</measure>
    <time_frame>Within 3 months prior to the TAVI procedure</time_frame>
    <description>incidence of severe bradycardia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left bundle branch block</measure>
    <time_frame>Within 3 months prior to the TAVI procedure</time_frame>
    <description>incidence of left bundle branch block</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Permanent pacemaker</measure>
    <time_frame>Within 3 months prior to the TAVI procedure</time_frame>
    <description>percentage of patients with an indication of permanent pacemaker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anticoagulation therapy</measure>
    <time_frame>Within 3 months prior to the TAVI procedure</time_frame>
    <description>percentage of patients with an indication for anticoagulation therapy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Arrythmia</condition>
  <arm_group>
    <arm_group_label>Prolonged continuous ECG monitoring</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will undergo a prolonged continuous ECG monitoring using the CardioSTAT® device within the 3 months prior to the TAVI procedure. The duration of the ECG monitoring will be of 1 week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ECG monitoring</intervention_name>
    <description>Prolonged continuous ECG monitoring using the CardioSTAT® device within the 3 months prior to the TAVI procedure</description>
    <arm_group_label>Prolonged continuous ECG monitoring</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with severe aortic stenosis accepted for a TAVI procedure by the Heart Team.

        Exclusion Criteria:

          -  Urgent TAVI procedure or logistic reasons precluding an ECG monitoring of at least 1
             week within the 3 months prior to the TAVI procedure.

          -  Prior permanent pacemaker.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>IUCPQ</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 13, 2018</study_first_submitted>
  <study_first_submitted_qc>June 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2018</study_first_posted>
  <last_update_submitted>March 25, 2020</last_update_submitted>
  <last_update_submitted_qc>March 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</investigator_affiliation>
    <investigator_full_name>Josep Rodes-Cabau</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>TAVI</keyword>
  <keyword>ECG monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

